Literature DB >> 2584352

Insulin-like growth factor-II in nonislet cell tumors associated with hypoglycemia: increased levels of messenger ribonucleic acid.

W L Lowe1, C T Roberts, D LeRoith, M T Rojeski, T J Merimee, S T Fui, H Keen, D Arnold, J Mersey, S Gluzman.   

Abstract

The role of insulin-like growth factor-II (IGF-II) in the hypoglycemia associated with nonislet cell tumors is controversial. In this study we have addressed this question by measuring the IGF-II mRNA levels in extracts of these tumors. Hybridization of a 32P-labeled IGF-II cDNA to a Northern blot of RNA from three nonislet cell tumors associated with hypoglycemia (a hemangiopericytoma, fibrosarcoma, and malignant mesenchymal tumor) demonstrated six hybridizing bands, 6.8, 5.6, 4.7, 3.6, 2.6, and 2.1 kilobases in length. These bands were similar to those described by others in a range of tumors and normal tissues. Tissue IGF-II mRNA levels were quantitated using a solution hybridization/RNase protection assay. IGF-II mRNA levels in the tumors were similar to the level present in one line of human hepatoblastoma-derived Hep G2 cells, 5- to 6-fold higher than that in another line of Hep G2 cells, and 2- to 3-fold higher than that in term placenta. In contrast, little or no IGF-II mRNA was detected in a nonfunctioning islet cell adenoma or normal spleen. There was no evidence for amplification of the IGF-II gene in the one tumor in which it was sought. These data suggest that nonislet cell tumors associated with hypoglycemia produce large amounts of IGF-II mRNA and that this IGF-II mRNA appears to be the product of an IGF-II gene, which is apparently normal in the region encoding mature IGF-II peptide.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584352     DOI: 10.1210/jcem-69-6-1153

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon.

Authors:  S Freier; O Weiss; M Eran; A Flyvbjerg; R Dahan; I Nephesh; T Safra; E Shiloni; I Raz
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 2.  Paraneoplastic endocrine syndromes: a review.

Authors:  Ronald A DeLellis; Ling Xia
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

3.  Spontaneous hypoglycaemia due to a pleural fibroma: role of insulin like growth factors.

Authors:  E A Masson; I A MacFarlane; D Graham; P Foy
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

4.  Hemangiopericytoma in the setting of acromegaly.

Authors:  W Jeffrey Elias; Isa M Hussaina; James B Chadduck; John A Jane; Edward R Laws; M Beatriz S Lopes
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

5.  Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?

Authors:  J Zapf; E Futo; M Peter; E R Froesch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

6.  Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography.

Authors:  R C Eastman; R E Carson; D G Orloff; C S Cochran; J F Perdue; M M Rechler; F Lanau; C T Roberts; J Shapiro; J Roth
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

7.  Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells.

Authors:  M A Steller; C H Delgado; Z Zou
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

8.  Metastatic secondary fibrosarcoma of bone responsive to repeated courses of Ifosfamide and associated with hypoglycemia.

Authors:  Elaine S Bouttell; N Wilson Rodger; Vivien H C Bramwell
Journal:  Sarcoma       Date:  2003

9.  The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches.

Authors:  W Zumkeller
Journal:  Sarcoma       Date:  1998
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.